Marco Toccaceli Blasi

Marco Toccaceli Blasi

Auto-generated profile, based on publicly available information

Marco Toccaceli Blasi

Department of Human Neuroscience, Sapienza University, Rome, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
MCMarco Canevelli
Marco Canevelli
MVMartina Valletta
Martina Valletta
MBMarco Toccaceli Blasi
Marco Toccaceli Blasi
GRGiulia Remoli
Giulia Remoli
GSGiulia Sarti
Giulia Sarti
GBGiuseppe Bruno
Giuseppe Bruno
Click on the article title to read more.

Verified
Journal Article
Open access
PDF file
MCMarco Canevelli
Marco Canevelli
GRGiulia Remoli
Giulia Remoli
IBIlaria Bacigalupo
Ilaria Bacigalupo
MVMartina Valletta
Martina Valletta
MBMarco Toccaceli Blasi
Marco Toccaceli Blasi
NVNicola Vanacore
Nicola Vanacore
The present study aimed to describe and discuss the state of the art of biomarker use in ongoing Alzheimer’s disease (AD) research. A review of 222 ongoing phase 1, 2, 3, and 4 protocols registered in the clinicaltrials.gov database was performed. All the trials (i) enrolling subjects with clinical disturbances and/or preclinical diagnoses falling within the AD continuum; and (ii) testing the efficacy and/or safety/tolerability of a therapeutic intervention, were analyzed. The use of biomarkers of amyloid deposition, tau pathology, and neurodegeneration among the eligibility criteria and/or study outcomes was assessed. Overall, 58.2% of ongoing interventional studies on AD adopt candidate biomarkers. They are mostly adopted by studies at the preliminary stages of the drug development process to explore the safety profile of novel therapies, and to provide evidence of target engagement and disease-modifying properties. The biologically supported selection of participants is mostly based on biomarkers of amyloid deposition, whereas the use of biomarkers as study outcomes mostly relies on markers of neurodegeneration. Biomarkers play an important role in the design and conduction of research protocols targeting AD. Nevertheless, their clinical validity, utility, and cost-effectiveness in the “real world” remain to be clarified.

17 December 2025 in The Lancet Healthy Longevity
Verified
Journal Article
Open access
XXXin Xia
Xin Xia
MEMaria Eriksdotter
Maria Eriksdotter
HZHenrik Zetterberg
Henrik Zetterberg
SKSilke Kern
Silke Kern
TSTobias Skillbäck
Tobias Skillbäck
LJLinus Jönsson
Linus Jönsson
This study aimed to examine the value of frailty status (defined by the frailty index) in informing the prognosis of people living with Alzheimer's disease. In this retrospective cohort study, we used the Swedish Registry for Cognitive/Dementia Disorders linked to other Swedish health-care registers to collect data from May 1, 2007, to Dec 31, 2020. We included people with mild cognitive impairment or Alzheimer's disease dementia, both with cerebrospinal fluid (CSF) biomarkers supporting Alzheimer's pathology. We excluded people living in an institution or those who did not have at least one Mini-Mental State Examination (MMSE). We constructed a 41-item frailty index, incorporating diseases, symptoms, polypharmacy, nutritional status, and care dependency. Individuals with frailty index scores of 0·25 or above were considered frail. The associations between frailty and MMSE trajectories, subsequent institutionalisation, and mortality were evaluated by jointly modelling longitudinal and survival data. We also examined whether frailty could modify the associations between CSF amyloid β42, phosphorylated tau181, and total tau and cognitive decline. The study included 7251 individuals (mean age 72·7 years, 4271 [58·9%] females, 2980 [41·1%] males). Frailty was associated with a 0·723-point (95% CI 0·250-1·196) lower baseline MMSE but not with the rate of MMSE decline. Frailty was associated with a hazard ratio of 1·91 (1·43-2·54) for institutionalisation and 2·41 (1·73-3·33) for mortality. Individuals living with frailty had a 1·3-year (0·9-1·7) shorter lifespan and a 1·0-year (0·8-1·3) shorter non-institutionalised lifespan. Associations between CSF biomarkers and MMSE trajectories did not differ by frailty status. Frailty, measured by the frailty index, predicted institutionalisation and mortality in people with Alzheimer's disease, but its absence of association with cognitive decline suggests neurodegeneration as the primary driver. Innovative Health Initiative Joint Undertaking and Vinnova.

12 August 2024 in GeroScience
Verified
Journal Article
Open access
PDF file
MBMarco Toccaceli Blasi
Marco Toccaceli Blasi
AAAlba Rosa Alfano
Alba Rosa Alfano
MSMartina Salzillo
Martina Salzillo
SBSimona Buscarnera
Simona Buscarnera
VRValeria Raparelli
Valeria Raparelli
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
Fatigue is a common and distressful symptom in older people and has been associated with adverse health outcomes. Nevertheless, its sex-specific pathophysiological underpinnings and clinical correlates have been scarcely investigated. We aimed to comprehensively explore the clinical and neurobiological determinants of fatigue in cognitively unimpaired older adults. A sex-stratified analysis was conducted to look for differences in the clinical expression of fatigue among women and men. Data on cognitively normal individuals were gathered from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 study. Fatigue was defined based on self-report at baseline. For each participant, information on sociodemographics, comorbidities, mood, cognitive performance, frailty, and biomarkers of brain pathology was collected. Logistic regression models, stratified by sex, were conducted to explore the factors associated with fatigue. Among the 291 participants selected, 44 subjects (15.1% of the total sample) self-reported fatigue at baseline. Subjects reporting fatigue were more likely women, had higher frailty degrees, and more severe depressive symptoms than those without fatigue. Moreover, they tended to have lower MRI hippocampus volumes. Among women, those reporting fatigue exhibited higher frailty levels, worse depression, and lower MRI hippocampus volumes relative to those without fatigue. Higher frailty degrees were also observed in men reporting vs. non-reporting fatigue. In the adjusted logistic regression model, more severe depression (OR 1.64, 95% CI 1.18–2.28; p < 0.01) and lower MRI hippocampus volumes (OR 0.41, 95% CI 0.19–0.90; p = 0.03) resulted independently associated with fatigue in women, while higher frailty degrees (OR 3.10, 95% CI 1.27–7.54 per 0.1 increase in a 39-item Frailty index; p = 0.01) in men. Fatigue is a complex symptom with a sex-specific pattern of clinical and neurobiological correlates. A better understanding of the underlying mechanisms of these associations is warranted to develop sex-informed approaches for personalized treatments.

23 April 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
MBMarco Toccaceli Blasi
Marco Toccaceli Blasi
MSMartina Salzillo
Martina Salzillo
SBSimona Buscarnera
Simona Buscarnera
FNFilippo Nuti
Filippo Nuti
CSCaterina Stanziale
Caterina Stanziale
GBGiuseppe Bruno
Giuseppe Bruno
Background: Neuropsychiatric symptoms (NPS) are among the most challenging manifestations of dementia. Currently available assessment tools often fail to fully capture their complexity. Thus, novel approaches are needed. Objective: The present study aimed to explore the application of a diary-based assessment of NPS in patients with dementia attending a memory clinic and compare this novel approach with the Neuropsychiatric Inventory (NPI) in terms of scores, time efficiency, and influence of potential confounders. Methods: All consecutive outpatients with dementia and NPS attending the Center for Cognitive Disorders and Dementia, Sapienza University of Rome, were considered for enrollment. Caregivers completed a specially designed NPS diary for one month. Subsequently, a standard NPI (sNPI) was administered, and two diary-based NPIs (dNPI-R1 and dNPI-R2) were independently reconstructed by trained raters. Scores were compared using repeated-measures ANOVA and Cochran's Q test. Multivariate regression models were conducted to examine the impact of covariates. In addition, the NPS diary was qualitatively analyzed, and caregivers provided structured feedback. Results: Forty patient-caregiver dyads completed the study procedures. The sNPI yielded higher scores and longer administration time than dNPIs. Diary-based assessments showed high inter-rater reliability and were less influenced by caregiver burden. Conclusions: The NPS diary offered an ecological, caregiver stress-resistant, reliable, time-efficient, and feasible evaluation of NPS. It allowed a detailed description of NPS, including temporal fluctuations, triggers, and resolution strategies. Integration of this complementary modality with standard evaluations allows a more comprehensive assessment of NPS in dementia.

3 April 2025 in Neurological Sciences
Verified
Journal Article
Open access
MBMarco Toccaceli Blasi
Marco Toccaceli Blasi
FRFabrizio Raffaele
Fabrizio Raffaele
DBDaniele Belvisi
Daniele Belvisi
SBSimona Buscarnera
Simona Buscarnera
GBGiuseppe Bruno
Giuseppe Bruno
MCMarco Canevelli
Marco Canevelli
Introduction: Patients with neurological disorders, particularly those who are chronologically and biologically older, may display highly varied clinical courses and trajectories. The present study explored the association between frailty and hospital outcomes among patients with acute neurological presentations admitted to an Italian university hospital. Materials and methods: A cross-sectional study considered all patients consecutively admitted to the Neurology Unit of the Policlinico Umberto I University Hospital of Rome (Italy). A 40-item Frailty Index (FI) was retrospectively developed based on the clinical information collected in the Emergency Department (ED). Data on hospitalization outcomes were prospectively collected during the patient’s stay at the Neurology Unit. Linear and logistic regression models were conducted to test the association between FI and hospital outcomes. Results: Overall, 185 participants (women 50.3%; mean age 68.6, SD 18.6 years) were included. FI scores ranged between 0 and 0.43, with a median value of 0.15 [IQR 0.10], and were positively correlated with age (Spearman’s rho 0.55, p < 0.001). In a linear regression model adjusted by age, sex, and diagnosis, FI was significantly associated with the number of days spent in the Neurology Unit (B 2.18, 95%CI 0.25–4.11, per 0.1 increase; p = 0.03). In bivariate logistic regression models adjusted by age, sex, and diagnosis, increasing FI scores were significantly associated with a lower likelihood of being discharged at home (OR 0.37, 95%CI 0.20–0.63, per 0.1 increase; p < 0.001), with higher odds of nosocomial infections (OR 1.67, 95%CI 1.05–2.73 per 0.1 increase; p = 0.03), and prescription of antibiotics (OR 1.77, 95%CI 1.11–2.92, per 0.1 increase; p = 0.02). Conclusion: Frailty is adversely associated with hospital outcomes in patients with acute neurological disorders. Assessing frailty could improve patient stratification, prognostication, and care planning, with a relevant impact on healthcare resources.